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OBJECTIVE — African-American (AA) children are hyperinsulinemic and insulin resistant
compared with American white (AW) children. Previously, we demonstrated that insulin secre-
tion relative to insulin sensitivity was 75% higher in AA compared with AW children, sug-
gesting that hyperinsulinemia in AA children is not merely a compensatory response to lower
insulinsensitivity.Theaimofthepresentinvestigationwastoassesswhetherglucose-stimulated
insulin response is higher in AA versus AW adolescents who have comparable in vivo insulin
sensitivity.
RESEARCH DESIGN AND METHODS — The hyperinsulinemic-euglycemic and hy-
perglycemic clamp techniques were utilized to assess ﬁrst- and second-phase insulin secretion.
Insulin secretion relative to insulin sensitivity was calculated as the glucose disposition index.
RESULTS — AA adolescents compared with their AW peers with comparable insulin sensi-
tivity and body composition had higher ﬁrst-phase insulin concentrations.
CONCLUSIONS — Thequantitativerelationshipbetweeninsulinsensitivityandﬁrst-phase
insulin appears to differ among AA and AW adolescents.
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A
frican-American (AA) adolescents
are hyperinsulinemic and at in-
creased risk for type 2 diabetes when
compared with American white (AW) ado-
lescents; however, the mechanisms under-
lying the increased risk in AA adolescents
are unclear. The objective of this study was
to assess whether ﬁrst- and second-phase
insulinconcentrationsarehigherinAAver-
sus AW youth if insulin sensitivity is not
different between the groups.
RESEARCH DESIGN AND
METHODS
ThestudywasapprovedbytheUniversity
of Pittsburgh Institutional Review Board.
Recruitment was done using posters, ﬂy-
ers, and newspaper advertisements. A to-
tal of 25 healthy AA adolescents (15 male
and10female,aged10.0–14.3years)and
23 healthy AW adolescents (12 male and
11 female, aged 9.9–14.3 years), Tanner
stages II–IV, participated. Findings from
some of the participants have been re-
ported (1). All subjects who participated
in this study are included in this report.
Exclusion criteria included ethnicity
other than AA or AW, diabetes or other
chronic diseases, and use of medications
affecting glucose metabolism. Ethnicity
was determined by self-report in three
generations of the participants’ families.
Metabolic studies
Participants underwent a 3-h 40 mU/m
2
per min hyperinsulinemic-euglycemic
clamp to assess insulin sensitivity and a
2-h hyperglycemic (12.5 mmol/l) clamp
to assess insulin secretion, as described
previously (2,3). Fasting hepatic glucose
production was evaluated before the hy-
perinsulinemic-euglycemic clamp as de-
scribed previously (2). Hepatic glucose
production (4), insulin-stimulated glu-
cose disposal (3), insulin sensitivity (3),
insulin clearance (3), ﬁrst- and second-
phaseinsulinconcentrations(2),andglu-
cosedispositionindex(2)werecalculated
as previously reported. Fasting blood
samples were obtained for lipid proﬁle,
insulin-like growth factor (IGF)-1, dehy-
droepiandrosteronesulfate(DHEA-S),es-
tradiol in females, and testosterone in
males.
Body composition analysis
Bodycompositionwasmeasuredbydual-
energy X-ray absorptiometry. Abdominal
adiposity was assessed with a 10-mm sin-
gle axial computed tomography scan at
the level of L4–5 vertebrae (4).
Biochemical measurements
Plasma glucose and insulin were mea-
sured as previously described (2). IGF-1
levels were measured at Esoterix. Fasting
lipid proﬁle was measured using stan-
dards of the Centers of Disease Control
andPrevention.Plasmafreefattyacidlev-
els and deuterium enrichment of glucose
in the plasma were determined as previ-
ouslyreported(4).Storedplasmasamples
from the hyperglycemic clamp for C-
peptidemeasurementweredestroyeddue
to freezer malfunction. Fasting plasma
samples for C-peptide from the euglyce-
mic clamp were by immunochemilumi-
nescent assay (Esoterix).
Statistical analysis
Comparisons between AA and AW ado-
lescents were made using two-tailed Stu-
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distributed variables. Appropriate non-
parametric tests were otherwise used.
Data are presented as means  SEM.
RESULTS
Physical, hormonal, and metabolic
characteristics
AA and AW adolescents had comparable
body composition (BMI 21.1  0.7 vs.
20.30.8kg/m
2,P0.45;percentbody
fat 21.0  2.3 vs. 22.4  2.2, P  0.66;
visceral adipose tissue 19.5  2.9 vs.
24.9  4.2 cm
2, P  0.48; fat mass
11.2  1.7 vs. 11.2  1.6 kg, P  0.96),
hormonal proﬁles (estradiol 159  47 vs.
126  20 pmol/l, P  0.53; testosterone
11.8  2.0 vs. 12.4  1.7 nmol/l, P 
0.83; DHEA-S 3,198  465 vs. 2,962 
375 nmol/l, P  0.85; IGF-1 55  5 vs.
49  3 nmol/l, P  0.42), and fasting
lipid proﬁles (cholesterol 4.09  0.13 vs.
4.09  0.18 mmol/l, P  0.97; HDL cho-
lesterol 1.30  0.03 vs. 1.32  0.05
mmol/l, P  0.60; LDL cholesterol
2.41  0.13 vs. 2.31  0.13 mmol/l, P 
0.61;triglycerides0.890.01vs.1.01
0.09 mmol/l, P  0.30).
Basal metabolic data
Fasting glucose and insulin levels from
thehyperinsulinemic-euglycemicandhy-
perglycemic clamps were averaged. Fast-
inginsulinwasnotdifferent(12211vs.
120  10 pmol/l, P  0.89) and fasting
glucose was lower (5.25  0.05 vs.
5.44  0.06 mmol/l, P  0.02) in AAs.
Fasting C-peptide (0.58  0.05 vs.
0.58  0.06 nmol/l, P  0.93), free fatty
acids(0.350.04vs.0.340.02mEq/l,
P  0.81), and hepatic glucose produc-
tion (3.1  0.4 vs. 3.0  0.1 mg   kg
1  
min
1, P  0.86) were not different.
Insulin sensitivity and clearance
During the hyperinsulinemic-euglycemic
clamp, steady-state plasma glucose (AA
5.61  0.03, AW 5.60  0.02 mmol/l,
P  0.67), insulin (AA 690  18, AW
636  36 pmol/l, P  0.21), insulin-
stimulated glucose disposal (AA 74.9 
4.4, AW 70.5  4.4 mol   kg fat-free
mass [FFM]
1   min
1; P  0.47), and
insulin sensitivity (AA 10.9  0.7, AW
11.8  1.0 mol   kg FFM
1   min
1 per
pmol/l; P  0.48) were not different (Fig.
1). Insulin clearance was lower in AAs
(17.9  0.8 vs. 20.7  1.1 mol   kg
FFM
1   min
1; P  0.05).
Insulin secretion and glucose
disposition index
During the hyperglycemic clamp, ﬁrst-
and second-phase glucose concentrations
were not different (ﬁrst-phase 11.9  0.2
mmol/l in AA vs. 12.2  0.1 mmol/l in
AW, P  0.25; second-phase 12.3  0.1
mmol/l in AA vs. 12.4  0.1 mmol/l in
AW, P  0.19). First-phase insulin con-
centration was higher in AAs (1,038 
126 vs. 636  108 pmol/l; P  0.002)
(Fig. 1). Second-phase insulin concentra-
tion was not different (AA 1,068  120
vs. AW 918  174 pmol/l; P  0.46).
After controlling for insulin clearance,
there remained a race difference in ﬁrst-
phase insulin (1,003  121 vs. 647 
123 pmol/l, P  0.05). The glucose dis-
position index was higher in AAs (10.3 
1.0 vs. 6.3  0.7 mol   kg FFM
1  
min
1, P  0.002).
CONCLUSIONS— Several studies
have demonstrated that AA children have
higher fasting and stimulated insulin lev-
els than AW children (2,5–7); however,
insulinsensitivitywaslowerinAAthanin
AW youth. Thus, the observed hyperin-
sulinemia in AAs was explained as a com-
pensatory response to insulin resistance.
In the current study, the observation of
higherinsulinsecretionwasmadedespite
similar insulin sensitivity. Differences in
insulin clearance could partly explain the
differences in ﬁrst-phase insulin concen-
trations; however, after adjusting for
clearance, there remained a race differ-
ence in ﬁrst-phase insulin concentration.
Insulin clearance in AA adolescents was
14% lower than in AWs, while ﬁrst-
phase insulin was 63% higher.
Potential causes of insulin hyperse-
cretion in AAs include dietary/lifestyle
factors, genetic differences, and socioeco-
nomic differences. Previously, we re-
ported dietary differences including
higher fat-to-carbohydrate ratio in AA
children (2). Increased fat-to-carbohy-
drate ratio correlated negatively with in-
sulinsensitivityandinsulinclearanceand
positively with ﬁrst-phase insulin levels
across racial groups (2). Gower et al. (8)
reportedthatgeneticadmixturewasinde-
pendently related to insulin sensitivity,
fastinginsulin,andacuteinsulinresponse
to glucose, indicating that hyperinsulin-
emia in AAs has a genetic basis.
The present study demonstrates that
AA adolescents have 1) 63% higher
ﬁrst-phase insulin and 2) 63% higher
glucosedispositionindexevenwhenthey
have insulin sensitivity comparable with
that of their AW peers. There appears to
be an upregulated -cell function in AA
adolescents, the mechanism(s) of which
should be investigated.
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